Affiliation: University of North Carolina
- Second assessment of NeuroAIDS in AfricaKevin Robertson
Department of Neurology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina 27599 7025, USA
J Neurovirol 14:87-101. 2008..The conference presentations summarized here highlight the need for further research on neuroAIDS in Africa and methods for assessing HIV-related neurological disorders...
- Neuropsychological assessment of HIV-infected populations in international settingsKevin Robertson
Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
Neuropsychol Rev 19:232-49. 2009....
- Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological StudyK Robertson
University of North Carolina, Chapel Hill, 27599 7025, USA
Clin Infect Dis 55:868-76. 2012..AIDS Clinical Trials Group (ACTG) A5199 compared the neurological and neuropsychological (NP) effects of 3 antiretroviral regimens in participants infected with human immunodeficiency virus type 1 (HIV-1) in resource-limited settings...
- Better quality of life with neuropsychological improvement on HAARTThomas D Parsons
AIDS Neurological Center, University of North Carolina, Chapel Hill, NC 27599 7025, USA
Health Qual Life Outcomes 4:11. 2006..Cognitive impairment can dramatically impact functional ability and day-to-day productivity. We assessed the relationship of quality of life (QOL) and neuropsychological functioning with successful HAART treatment...
- Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in UgandaNoeline Nakasujja
Department of Public Health Sciences, Karolinska Institute, Stockholm, Sweden
BMC Psychiatry 10:44. 2010..Initiation of highly active antiretroviral therapy (HAART) may have an effect on the prevalence and the change over time of depression symptoms and cognitive impairment among HIV-positive individuals...
- Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapyChristina M Marra
Harborview Medical Center, University of Washington, Seattle, WA, USA
BMC Infect Dis 7:37. 2007....
- Pattern of neuropsychological performance among HIV positive patients in UgandaKevin R Robertson
Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
BMC Neurol 7:8. 2007..The purpose of the current study was to evaluate the pattern of neuropsychological performance in a sample of HIV positive patients in comparison to HIV negative control subjects in Uganda...
- NeuroAIDS in AfricaKevin Robertson
Department of Neurology, University of North Carolina, Chapel Hill, North Carolina 27599 7025, USA
J Neurovirol 16:189-202. 2010....
- The prevalence and incidence of neurocognitive impairment in the HAART eraKevin R Robertson
Department of Neurology, UNC, Chapel Hill, North Carolina 27599, USA
AIDS 21:1915-21. 2007..The effects of HAART on neurological disease are less well understood. The aim of this study was to assess the prevalence and incidence of neurocognitive impairment in individuals who initiated HAART as part of an AIDS clinical trial...
- HIV, antiretroviral therapies, and the brainKevin J Liner
Department of Neurology, University of North Carolina, 170 Manning Drive, Chapel Hill, NC 27599 7025, USA
Curr HIV/AIDS Rep 7:85-91. 2010....
- Effects of antiretroviral therapy on cognitive impairmentKevin J Liner
School of Medicine, University of North Carolina at Chapel Hill, 3114 Bioinformatics Building CB7025, Neurology, Chapel Hill, NC 27599 7025, USA
Curr HIV/AIDS Rep 5:64-71. 2008..When to start antiretrovirals for the maximum cognitive benefit remains to be determined...
- Assessment of neuroAIDS in the international settingKevin R Robertson
Neurology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7025, USA
J Neuroimmune Pharmacol 2:105-11. 2007..There are a number of barriers in the assessment of neurological and neurocognitive effects in resource limited settings and some of these will be addressed...
- Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohortK R Robertson
Department of Neurology, University of North Carolina, 2128 Physician Office Building, Chapel Hill, NC 27599 7025, USA
Neurology 74:1260-6. 2010..Prior studies have shown improved neurocognition with initiation of antiretroviral treatment (ART) in HIV. We hypothesized that stopping ART would be associated with poorer neurocognitive function...
- A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settingsKevin Robertson
University of North Carolina, Chapel Hill, NC 27599 7025, USA
J Neurovirol 17:438-47. 2011..Longitudinal follow-up after antiretroviral treatment initiation may help to define more broadly the role of HIV in these differences as well as the impact of treatment on performance...
- Timed Gait test: normative data for the assessment of the AIDS dementia complexKevin R Robertson
AIDS Neurological Center and Department of Neurology, School of Medicine, University of North Carolina at Chapel Hill, NC 27599 7025, USA
J Clin Exp Neuropsychol 28:1053-64. 2006..These normative data should prove useful in both recognition of ADC and treatment response. Given its minimal training requirements, the Timed Gait would have utility in resource limited settings...
- Thoughts of death and suicidal ideation in nonpsychiatric human immunodeficiency virus seropositive individualsKevin Robertson
AIDS Neurological Center, 3114 Bioinformatics, Departments of Neurology and Psychiatry, University North Carolina, School of Medicine, Chapel Hill, North Carolina 27599 7025, USA
Death Stud 30:455-69. 2006..Suicidal ideation did not increase with advancing disease. The high prevalence of suicidal ideation suggests inclusion of its assessment in HIV treatment regardless of stage...
- Assessment of neuroAIDS in AfricaKevin Robertson
AIDS Neurological Center, 3114 Bioinformatics, Department of Neurology, University of North Carolina, School of Medicine, Chapel Hill, North Carolina 27599 7025, USA
J Neurovirol 11:7-16. 2005
- The International HIV Dementia Scale: a new rapid screening test for HIV dementiaNed C Sacktor
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
AIDS 19:1367-74. 2005..The objective of this study was to evaluate the sensitivity and specificity of a new screening test for HIV dementia, the International HIV Dementia Scale (IHDS) in cohorts from the US and Uganda...
- Longitudinal neuropsychological test performance among HIV seropositive individuals in UgandaNed Sacktor
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
J Neurovirol 19:48-56. 2013..Possible reasons for this include practice effects among the no-ART group as well as improvements in their mood and overall quality of life...
- Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease coursePatrick R Harrington
Lineberger Comprehensive Cancer Center and UNC Center for AIDS Research, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina 27599 7295, USA
AIDS 23:907-15. 2009....
- Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performanceChristina M Marra
Department of Neurology, University of Washington School of Medicine, Seattle, USA
AIDS 23:1359-66. 2009..To determine whether antiretroviral regimens with good central nervous system (CNS) penetration control HIV in cerebrospinal fluid (CSF) and improve cognition...
- HIV-associated cognitive impairment in sub-Saharan Africa--the potential effect of clade diversityNed Sacktor
Department of Neurology, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD 21224, USA
Nat Clin Pract Neurol 3:436-43. 2007..Further studies are needed to determine the true prevalence of HIV dementia in sub-Saharan Africa and to establish whether specific clade subtypes might influence the presentation of neurological complications...
- Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotectionRick B Meeker
Department of Neurology, University of North Carolina, CB 7025, 6113 Neuroscience Research Bldg, 115 Mason Farm Road, Chapel Hill, NC 27599, USA
J Neurovirol 17:258-73. 2011....
- Longitudinal characterization of depression and mood states beginning in primary HIV infectionJessica A Gold
Department of Neurology, Yale University School of Medicine, 300 George Street, Room 8300C, New Haven, CT, USA
AIDS Behav 18:1124-32. 2014..Neither neuropsychological performance nor disease biomarkers correlated with depressed mood. Mood indices did not improve over time in the presence of ART. ..
- Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infectionMichael J Peluso
Department of Neurology, Yale School of Medicine, New Haven, Connecticut, USA
J Infect Dis 207:1703-12. 2013..Cerebrospinal fluid (CSF) and neuroimaging abnormalities demonstrate neuronal injury during chronic AIDS, but data on these biomarkers during primary human immunodeficiency virus (HIV) infection is limited...
- HIV subtype is not associated with dementia among individuals with moderate and advanced immunosuppression in Kampala, UgandaNed Sacktor
Department of Neurology, Johns Hopkins Bayview Medical Center, 301 Building, Suite 2100, 4940 Eastern Ave, Baltimore, MD, 21224, USA
Metab Brain Dis 29:261-8. 2014..There was no association between HIV subtype and dementia among HIV+ individuals with moderate and advanced immunosuppression. Future studies should be performed to confirm these results...
- Antiretroviral neurotoxicityKevin Robertson
Department of Neurology, University of North Carolina, Chapel Hill, NC 27599, USA
J Neurovirol 18:388-99. 2012..No additive effects were seen with combinations used clinically. These data provide initial evidence useful for the development of treatment strategies that might reduce the risk of antiretroviral neurotoxicity...
- Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementiaKimberly Ritola
University of North Carolina at Chapel Hill, UNC Center for AIDS Research, Chapel Hill, NC 27599 7295, USA
J Virol 79:10830-4. 2005..Alternatively, HAD may be associated with a more pronounced state of immunosuppression that permits more extensive replication and independent evolution within the CNS compartment...
- Neurologic and neurodevelopmental manifestations of pediatric HIV/AIDS: a global perspectiveAnnelies Van Rie
Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, 2104F Mc Gavran Greenberg Hall, Chapel Hill, NC 27599 7435, USA
Eur J Paediatr Neurol 11:1-9. 2007..Neurotropic HIV-1 likely develops distinct genotypic characteristics in response to this unique environment. We reviewed the literature on pediatric neuroAIDS and identified gaps in the current knowledge...
- Editorial comment: déjà vu--neurologic complications of HIV infection in the expanding epidemicRichard W Price
AIDS Read 15:144. 2005
- Clinical validation of the NeuroScreenRonald J Ellis
Department of Neurosciences, UCSD AntiViral Research Center and HIV Neurobehavioral Research Center, University of California, San Diego, California 92103, USA
J Neurovirol 11:503-11. 2005..However, because it yields substantial numbers of false positives and negatives, the NeuroScreen may be less useful in evaluating individual patients...
- Neurological complications of HIV infection and AIDS: current and future perspectivesPaola Cinque
Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy
J Neurovirol 11:1-5. 2005
- Motor based assessment of neurocognitive functioning in resource-limited international settingsThomas D Parsons
Center corrected for Creative Technologies, University of Southern California, Marina del Rey, CA 90292, USA
J Clin Exp Neuropsychol 29:59-66. 2007..Motor battery sensitivity to impairment diagnosis was 0.79 and specificity was 0.76. A motor battery may have broader utility to diagnose and monitor HIV related neurocognitive disorders in international settings...
- HIV DNA and dementia in treatment-naïve HIV-1-infected individuals in Bangkok, ThailandBruce Shiramizu
Hawaii AIDS Clinical Research Program, University of Hawaii, Honolulu, HI, USA
Int J Med Sci 4:13-8. 2007..These results are consistent with a previous report among HAART-experienced subjects, thus further implicating HIV DNA in the pathogenesis of HAD...
- HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patientsJ Allen McCutchan
University of California San Diego, 150 West Washington Street, San Diego, CA 92103, USA
AIDS 21:1109-17. 2007..Epidemiological observations suggest that neuropsychological impairment might progress despite successful HAART therapy, but available prevalence estimates are based on populations that were selected for impairment...
- Assessment of human papillomavirus mRNA detection over time in cervical specimens collected in liquid based cytology mediumKate S Cuschieri
Specialist Virology Centre, New Royal Infirmary of Edinburgh, 2nd Floor Microbiology, 51 Little France Crescent, Edinburgh EH16 4SA, UK
J Virol Methods 124:211-5. 2005..It is concluded that HPV RNA in routinely collected LBC specimens in PreservCyt can be detected for at least 14 days from sample collection...